{"files"=>["http://files.figshare.com/1623574/File_S1.docx"], "pos_in_sequence"=>0, "stats"=>{"downloads"=>0, "page_views"=>4, "likes"=>0}, "users"=>[], "links"=>[], "tags"=>["epidemiology", "Bacterial diseases", "Diagnostic medicine", "Economic epidemiology", "research design", "Clinical research design", "tuberculosis", "Infectious diseases", "diagnostics", "Cross-sectional studies", "brazil"], "title"=>"<p>Market Assessment of Tuberculosis Diagnostics in Brazil in 2012</p>", "figshare_url"=>"http://figshare.com/articles/_Market_Assessment_of_Tuberculosis_Diagnostics_in_Brazil_in_2012_/1129346", "defined_type"=>3, "doi"=>["http://dx.doi.org/10.1371/journal.pone.0104105.s001"], "published_date"=>"2014-08-06 03:11:06", "article_id"=>1129346, "categories"=>["Biological Sciences"], "description"=>"<div><section><p>Background</p><p>Improved diagnostics for the diagnosis of tuberculosis (TB) are urgently needed. However, test developers and investors require market size data to support new product development. This study assessed the served available market for TB diagnostics in Brazil in 2012 and the market segmentation in the public and private sectors.</p></section><section><p>Methods</p><p>Data were collected on test volumes done in the public and private sectors for the diagnosis of latent and active TB, drug susceptibility testing and treatment follow-up. Tests included were tuberculin skin tests, interferon-gamma releases assays, smear microscopy, solid and liquid cultures, nucleic acid amplification tests and phenotypic drug susceptibility tests. The data were collected by means of an electronic survey via the Brazilian State laboratories and from sales information provided by manufacturers. Test costs for the public sector were calculated using a components approach, while costs for the private sector were based on prices paid by patients. The overall market value (expenditure) for the entire country was calculated using the public sector test costs.</p></section><section><p>Results</p><p>During 2012, an estimated total of 2.4 million TB diagnostic tests were done in Brazil, resulting in an estimated overall market value of USD 17.2 million. The public sector accounted for 91% of the test volumes and 88% of the market value. Smear microscopy was the most commonly test (n&#8202;=&#8202;1.3 million; 55% of total) at an estimated value of USD 3.7 million. Culture overall (n&#8202;=&#8202;302,761) represented 13% of test volumes and 40% (USD 6.9 million) of the market value. On average, USD 208 was spent on TB diagnostics for every notified TB patient in Brazil, in 2012.</p></section><section><p>Conclusion</p><p>The TB diagnostics market value in Brazil in 2012 was over USD 17 million. These study results will help test developers to understand the current and potential market for replacement or add-on diagnostic technologies.</p></section></div>"}